Since May 2024, Zypadhera, an injectable Olanzapine prolonged liberation with 300 mg and 405 mg dosages, has experienced supply tensions linked to production and quality problems in the manufacturer Cheplapharm. Its discount is gradually planned for September 2025. To limit the impact on patients, ANSM, in collaboration with the prescribers and the laboratory, has issued precise recommendations.
Favor the oral route
It is strongly advised by prescribers to no longer initiate new treatments by Zypadhera in order to preserve stocks for patients already under treatment.
In addition, it is recommended to favor, when possible, an oral olanzapine relay or another antipsychotic.
Oral olanzapine must be established at low doses on the scheduled date of the next injection, with reinforced clinical monitoring during the first two months. Available in town, these alternatives make it possible to ensure therapeutic continuity. The ANSM recalls that, due to the long time of action of Zypadhera (6 to 8 months after injection), this oral relay remains the privileged solution, in particular in the event of subsequent recovery of the injectable treatment.
Vigilance at the counter
At the pharmacy, it is essential to exchange with patients on therapeutic continuity by directing secure oral relays.
We must also remain vigilant about the potential adverse effects linked to the change of galleic form and encourage patients and healthcare professionals to report any incident via the dedicated portal.